Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT02937701 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02937701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02937701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects With Moderate to Severe Rheumatoid Arthritis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
October 10, 2016
Completion date
August 13, 2018
Enrollment
558 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid